Clinical TrialMay 27, 2026, 04:37 PM
Autonomix Medical Pauses Clinical Trial; Corrects Financial Error
AI Summary
Autonomix Medical, Inc. has reported a correction of an error in previously issued financial statements within its 10-K filing. The development-stage medical device company also announced a pause in enrollment for its PoC 2 clinical expansion study for pancreatic cancer pain due to observed variability in early clinical outcomes. A revised clinical protocol, focusing on severe pancreatic cancer pain, was approved in April 2026, with U.S.-based clinical trials anticipated to commence in late 2026, subject to financing. The company, which has no product sales revenue, aims for regulatory clearance around 2028.
Key Highlights
- Financial statements reflect correction of an error to previously issued statements.
- Aggregate market value of non-affiliate voting equity was $6,307,279.
- 11,409,344 shares of common stock outstanding as of May 21, 2026.
- Paused enrollment in PoC 2 clinical expansion study due to outcome variability.
- Revised clinical protocol approved April 9, 2026, focusing on severe pancreatic cancer pain.
- Anticipates U.S.-based clinical trials to commence late 2026, subject to financing.
- Regulatory clearance potentially in 2028 timeframe via De Novo pathway.
- Holds 75 issued patents and 37 pending patent applications across 18 families.
Price Impact
More from AMIX